Therapy Areas: Autoimmune
Antengene reports first patient dosed in Phase I study of ATG-201 in B cell-mediated autoimmune diseases
6 November 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996) announced on Thursday that the first patient has been dosed in China in the Phase I ATTRACT study evaluatin...
Chinese regulator accepts Lynk Pharmaceuticals' New Drug Application for zemprocitinib in RA treatment
6 November 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, announced on Thursday that the New Drug Application (NDA) for i...
Lynk Pharmaceuticals reports positive Phase III trial results for zemprocitinib in rheumatoid arthritis
28 October 2026 - Lynk Pharmaceuticals Co Ltd, a Chinese drug development company focused on immune and inflammatory diseases, on Tuesday announced positive long-term results from its pivotal Phase II...
Vivacta Bio and Grit Bio's in vivo CAR-T therapy GT801 receives US FDA Orphan Drug Designation for autoimmune haemolytic anaemia
19 October 2026 - Vivacta Biotechnology (Shanghai) Co Ltd (Vivacta Bio), a China-based company spun out of the in vivo CAR-T platform of Beijing Grit Biotherapeutics Co Ltd (Grit Bio), announced on Sa...
FDA approves Genentech's Enspryng as first at-home subcutaneous treatment for thyroid eye disease
16 October 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that it has received US Food and Drug Administration (FDA) approval fo...
argenx reports positive Phase 2 results for FB102 in coeliac disease
8 October 2026 - European immunology company argenx SE (EBR & NASDAQ: ARGX) on Thursday reported positive top-line results from a Phase 2 study of FB102, a first-in-class CD122 inhibitor, in adult...